

IN THE CLAIMS:

Please amend the claims and add new claims 54 to 63 as follows:

1. (Currently amended) A purified polypeptide comprising an antibody, or a functional fragment thereof, ~~that induces apoptosis of a neoplastic cell to which it binds, but does not induce apoptosis of a non-neoplastic cell~~, wherein said antibody or functional fragment specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells ~~and not to non-neoplastic cells~~, and comprises a sequence at least 85% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3.

2. (Currently amended) The polypeptide antibody or functional fragment of claim 1, wherein said ~~neoplastic cell is a colorectal adenocarcinoma, ovarian cancer, squamous cell lung carcinoma, or lobular mammary carcinoma cell~~ antibody or functional fragment inhibits cell proliferation of CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), or COLO-206F (DSMZ Accession No. ACC 21) cells.

3. (Cancelled)

4. (Currently amended) The purified polypeptide ~~antibody or functional fragment~~ of claim 1, wherein said ~~polypeptide inhibits cell proliferation~~ antibody or functional fragment induces apoptosis of a neoplastic cell to which it binds when bound to a neoplastic cell, but does not inhibit cell proliferation of a non-neoplastic cell at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells.

5. (Cancelled).

6. (Cancelled).

7. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said polypeptide antibody or functional fragment comprises a sequence that is substantially at least 90% identical to the amino acid sequence of SEQ ID NO:1.

8. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said polypeptide antibody or functional fragment comprises a sequence that is substantially at least 90% identical to the amino acid sequence of SEQ ID NO:3.

9. (Currently amended) A purified polypeptide comprising an antibody, or functional fragment thereof, wherein said polypeptide antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:1.

10. (Currently amended) A purified polypeptide comprising an antibody, or functional fragment thereof, wherein said polypeptide antibody or functional fragment comprises the amino acid sequence of SEQ ID NO:3.

11. (Currently amended) A purified polypeptide comprising an antibody, or functional fragment thereof, wherein said polypeptide antibody or functional fragment comprises the amino acid sequence of SEQ ID NOS:1 and 3.

12. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said antibody or functional fragment is a human antibody.

13. (Currently amended) The purified polypeptide antibody of claim 1, wherein said antibody is a monoclonal antibody.

14. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said polypeptide ~~is a~~ functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells is selected from the group consisting of V_{LH} , V_{HH} , F_V , $[[F_C]]$ Fab, Fab', and $F(ab')_2$.

15. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said polypeptide ~~is a~~ functional fragment that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells ~~comprising~~ comprises a fragment that is substantially at least 90% identical to the sequence of SEQ ID NO:1 or SEQ ID NO:3.

16. (Currently amended) The purified polypeptide antibody or functional fragment of claim 1, wherein said polypeptide ~~is a~~ functional fragment that specifically binds to at least one

of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells comprising comprises a fragment of the sequence of SEQ ID NO: 1 or SEQ ID NQ:3.

17.-53. (Canceled)

54. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 90% identical to the amino acid sequence of SEQ ID NO:3.

55. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

56. (New) The purified antibody or functional fragment of claim 1, wherein said antibody or functional fragment comprises a sequence at least 95% identical to the amino acid sequence of SEQ ID NO:1 and a sequence at least at least 95% identical to the amino acid sequence of SEQ ID NO:3.

57. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:1.

58. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 85% identical to 100 contiguous amino acids of SEQ ID NO:3.

59. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:1.

60. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 90% identical to 100 contiguous amino acids of SEQ ID NO:3.

61. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:1.

62. (New) The purified antibody or functional fragment of claim 1, wherein said functional fragment comprises a sequence that is at least 95% identical to 100 contiguous amino acids of SEQ ID NO:3.

63. (New) A purified antibody, or a functional fragment thereof that specifically binds to at least one of HT-29 (ATCC Accession No. HTB-38; DSMZ Accession No. ACC 299), CACO-2 (ATCC Accession No. HBT-37; DSMZ Accession No. ACC 169), COLO-320 (DSMZ Accession No. ACC 144), COLO-206F (DSMZ Accession No. ACC 21), or COLO-678 (DSMZ Accession No. 194) cells, wherein the antibody comprises SEQ ID NO:1 and SEQ ID NO:3 with a conservative amino acid substitution in either SEQ ID NO:1 or SEQ ID NO:3.

64. (New) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:1.

65. (New) A purified polypeptide comprising the amino acid sequence of SEQ ID NO:3.